Hostname: page-component-8448b6f56d-c4f8m Total loading time: 0 Render date: 2024-04-19T20:33:14.336Z Has data issue: false hasContentIssue false
  • English
  • Français

Long-Term Efficacy of Botulinum A Toxin for Blepharospasm and Hemifacial Spasm

Published online by Cambridge University Press:  02 December 2014

Harmeet S. Gill  and
Stephen P. Kraft
Harmeet S. Gill
Affiliation:
Department of Ophthalmology and Vision Sciences, University Health Network and the University of Toronto, Toronto, Ontario, Canada
Stephen P. Kraft*
Affiliation:
Department of Ophthalmology and Vision Sciences, University Health Network and the University of Toronto, Toronto, Ontario, Canada
*
The Hospital for Sick Children, 555 University Avenue, Toronto, Ontario, M5G 1X8Canada.
Rights & Permissions [Opens in a new window]

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Objective:

To determine whether the duration of relief from symptoms in patients with essential blepharospasm (EB) or hemifacial spasm (HFS) who receive serial treatments with botulinum toxin type A (BtA) changes over the long-term.

Methods:

Retrospective longitudinal comparative analysis. The main outcome measure is the mean duration of relief from symptoms after an injection with BtA. Participants included 34 patients who received 30 or more serial BtA treatments for facial dyskinesia (EB or HFS). Repeated measures and linear regression analyses were used to determine trends and the mean duration of relief from symptoms was compared between early (first ten effective treatments) and late (last ten treatments) sessions in each group.

Results:

In the EB group (18 patients), the mean duration of relief was 13.5 weeks for the early and 11.4 weeks for the late sessions (P=0.04). In the HFS group (16 patients) the mean duration of relief was 12.4 weeks in both treatment periods (P=0.91). The duration of relief had a small negative correlation with mean late session BtA dose in the EB group (P=0.03) but no correlation in the HFS group (P=0.12).

Conclusions:

There was a trend towards a decreased duration of relief from symptoms in patients with EB over the long-term, but no changes for HFS. The treatment remains effective in relieving symptoms and signs for both conditions.

Résumé:

RÉSUMÉ:Objectif:

Le but de l’étude était de déterminer si la durée de soulagement des symptoms chez les patients atteints de blépharospasme essentiel (BSE) ou de spasme hémifacial (SHF) qui ont reçu des traitements en série par la toxine botulique de type A (BtA) change à long terme.

Méthodes:

Il s’agit d’une etude longitudinale rétrospective. L’issue primaire était la durée moyenne de soulagement des symptômes après une injection de BtA. L’étude porte sur 34 patients qui ont reçu plus de 30 traitements en série au moyen de la BtA, pour des dyskinésies faciales (BSE ou SHF). Des mesures répétées et des analyses de régression linéaires ont été utilisées pour déterminer la tendance. La durée moyenne du soulagement des symptômes a été comparée entre les première sessions (les 10 premiers traitements efficaces) et les sessions tardives (10 derniers traitements) dans chaque groupe.

Résultats:

Dans le groupe BSE (18 patients), la durée moyenne de soulagement était de 13,5 semaines pour les premiers traitements et de 11,4 semaines pour les derniers (p = 0,04). Dans le groupe SHF (16 patients), la durée moyenne de soulagement était de 12,4 semaines au cours des deux périodes de traitement (p = 0,91). La durée du soulagement avait une faible corrélation négative avec la dose moyenne de BtAdes dernières sessions dans le groupe BSE (p = 0,03) mais pas de corrélation dans le groupe SHF (p = 0,12).

Conclusions:

Il existait une tendance à long terme vers une durée moindre du soulagement chez les patients atteints de BSE mais pas de changement chez ceux atteints de SHF. Le traitement demeure efficace pour soulager les symptômes et les signes de ces deux maladies.

Type
Original Article
Information
Canadian Journal of Neurological Sciences , Volume 37 , Issue 5 , September 2010 , pp. 631 - 636
Copyright
Copyright © The Canadian Journal of Neurological 2010

References

1. Jankovic, J, Ford, J. Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients. Ann Neurol. 1983;13:402–11.Google Scholar
2. Berardelli, A, Rothwell, JC, Day, BL, Marsden, CD. Pathophysiology of blepharospasm and oromandibular dystonia. Brain. 1985;108: 593–608.Google Scholar
3. Adler, CH, Zimmerman, RA, Savino, PJ, Bernardi, B, Bosley, TM, Sergott, RC. Hemifacial spasm: evaluation by magnetic resonance imaging and magnetic resonance tomographic angiography. Ann Neurol. 1992;32:502–6.CrossRefGoogle ScholarPubMed
4. Elston, JS. The management of blepharospasm and hemifacial spasm. J Neurol. 1992;239:5–8.Google Scholar
5. Taylor, JDN, Kraft, SP, Kazdan, MS, Flanders, M, Cadera, W, Orton, RB. Treatment of blepharospasm and hemifacial spasm with botulinum A toxin: a Canadian multicentre study. Can J Ophthalmol. 1991;26:133–8.Google ScholarPubMed
6. Carruthers, J, Stubbs, HA. Botulinum toxin for benign essential blepharospasm, hemifacial spasm and age-related lower eyelid entropion. Can J Neurol Sci. 1987;14:42–5.Google Scholar
7. Carruthers, J. Ophthalmologic use of botulinum A exotoxin. Can J Ophthalmol. 1985;20:135–41.Google Scholar
8. Lingua, RW. Sequelae of botulinum toxin injection. Am J Ophthalmol. 1985;100:305–7.Google Scholar
9. Kraft, SP, Lang, AE. Botulinum toxin injections in the treatment of blepharospasm, hemifacial spasm, and eyelid fasciculations. Can J Neurol Sci. 1988;15:276–80.CrossRefGoogle ScholarPubMed
10. Ainsworth, JR, Kraft, SP. Long-term changes in duration of relief with botulinum toxin treatment of essential blepharospasm and hemifacial spasm. Ophthalmology. 1995;102:2036–40.Google Scholar
11. Dutton, JJ, Buckley, EG. Long-term results and complications of botulinum A toxin in treatment of blepharospasm. Ophthalmology. 1988;95(12):1529–34.Google Scholar
12. Vogt, T, Lussi, F, Paul, A, Urban, P. Long-term therapy of focal dystonia and facial hemispasm with botulinum toxin A. Nervenarzt. 2008;79:912–17.Google Scholar
13. Mauriello, JA, Coniaris, H, Haupt, EJ. Use of botulinum toxin in the treatment of one hundred patients with facial dyskinesias. Ophthalmology. 1987;94:976–9.Google Scholar
14. Shorr, N, Seiff, SR, Kopelman, J. The use of botulinum toxin in blepharospasm. Am J Ophthalmol. 1985;99:542–6.Google Scholar
15. Drummond, GT, Hinz, BJ. Botulinum toxin for blepharospasm and hemifacial spasm: stability of duration of effect and dosage over time. Can J Ophthalmol. 2001;36(7):398–403.Google Scholar
16. Hsiung, GYR, Das, SK, Ranawaya, R, Lafontaine, AL, Suchowersky, O. Long-term efficiacy of botulinum toxin A in treatment of various movement disorders over a 10-year period. Movement Disord. 2002;17(6):1288–93.Google Scholar
17. Calace, P, Cortese, G, Piscopo, R, Della Volpe, G, Gagliardi, V, Magli, A, et al. Treatment of blepharospasm with botulinum neurotoxin type A: long-term results. Eur J Ophthalmol. 2003;13(4):331–6.Google Scholar
18. Nussgens, Z, Roggenkamper, P. Long-term treatment of blepharospasm with botulinum toxin type A. Ger J Ophthalmol. 1995;4:363–7.Google Scholar
19. Jitpimolmard, S, Tiamkao, S, Laopaiboon, M. Long term results of botulinum toxin type A (Dysport) in the treatment of hemifacial spasm: a report of 175 cases. J Neurol Neurosurg Psychiatry. 1998;64:751–7.CrossRefGoogle ScholarPubMed
20. Flanders, M, Chin, D, Boghen, D. Botulinum toxin: preferred treatment for hemifacial spasm. Eur Neurol. 1993;33(4):316–19.CrossRefGoogle ScholarPubMed
21. Defazio, G, Abbruzzese, G, Girlanda, P, Vacca, L, Curra, A, De Salvia, R, et al. Botulinum toxin A treatment for primary hemifacial spasm. A 10-year multicenter study. Arch Neurol. 2002;59: 418–20.Google Scholar
22. Jankovic, J, Schwartz, K. Botulinum toxin injections for cervical dystonia. Neurology. 1990;40:277–80.Google Scholar
23. Tan, EK, Jankovic, J. Bilateral hemifacial spasm: a report of five cases and a literature review. Movement Disord. 1999;14(2): 345–9.Google Scholar
24. Bonner, PH, Friedli, AF, Baker, RS. Botulinum A toxin stimulates neurite branching in nerve-muscle cocultures. Dev Brain Res. 1994;79:39–46.Google Scholar
25. Kessler, KR, Benecke, R. Botulinum toxin: from poison to remedy. Neurotoxicology. 1997;18(3):761–70.Google Scholar
26. Borodic, G, Johnson, E, Goodenough, M, Schantz, E. Botulinum toxin therapy, immunological resistance, and problems with available materials. Neurology. 1996;46:26–30.Google Scholar
27. Cakmur, R, Ozturk, V, Uzunel, F, Donmez, B, Idiman, F. Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm. J Neurol. 2002;249:64–8.Google Scholar
28. Jankovic, J. Pretarsal injection of botulinum toxin for blepharospasm and apraxia of eyelid opening. J Neurol Neurosurg Psychiatry. 1996;60(6):704.Google Scholar